AlphAIAlphAI — Financial news for AI agents
tradingpedia.comNOV 32 min read$RVTY

Revvity Shares Jump After Strong Q3, Raises Outlook

Revvity shares rose 8.8% premarket after Q3 2026 earnings beat expectations, with adjusted EPS at $1.37 and revenue at $729M. The company raised FY 2026 guidance, targeting $5.40–$5.45 EPS and $2.86B revenue. Life Sciences segment grew 11%, and operating margin improved to 13.1%. CEO attributed results to strong execution. TD Cowen raised its price target to $175 in October.

Original reporting
tradingpedia.com
Published Nov 3, 2026, 1:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 2:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$RVTY
Bullish
high confidence
Mentioned
$RVTY
Relevance
8/10
AlphAI data visualization · based on tradingpedia.com
Decision brief

The 30-second read

$RVTYBullishHigh
01

Why it matters

The earnings surprise and guidance upgrade are likely to sustain short‑term buying pressure, though investors should watch upcoming Investor Day for further guidance.

02

Market read

Strong earnings and guidance raise Revvity's valuation prospects and may influence related life‑sciences stocks.

03

What to watch

Potential headwinds from supply chain constraints or slower adoption of new products.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Revvity reported Q3 2026 results that beat expectations and lifted its full‑year outlook, prompting a notable pre‑market rally.

Company-level read

Ticker impact

$RVTYBullishHigh confidence
Context

Q3 2026 earnings beat and raised FY guidance caused an 8.8% pre‑market surge.

Expected impact

upward pressure as investors price in stronger earnings and higher outlook

Evidence & confidence

Adjusted EPS $1.37 beat consensus, revenue $729M beat $694.7M, and FY EPS guidance raised to $5.40‑$5.45.

Market effects

Sector

Life‑sciences segment shows strong growth, may lift peers in diagnostics and lab equipment.

Regional

Positive for US biotech and life‑sciences stocks, limited broader market effect.

Global

Modest; primarily impacts Revvity and similar US‑listed life‑sciences firms.

Counterpoint

What could challenge this read

The raise in guidance may already be priced in; risk of missing expectations later in the year.

Key entities

  • Company
    Revvity Inc.

    Life‑sciences company reporting earnings.

  • Executive
    Prahlad Singh

    CEO of Revvity who commented on the results.

Read at source← All news

StoryRevvity beats Q3 expectations and raises 2026 guidance

Also covered by

4 outlets

Related articles

NOV 3
$RVTYMed

Revvity, Inc. Q3 2026 Earnings Call Summary

Revvity, Inc. reported Q3 2026 earnings, highlighting a 9% organic growth in Life Sciences, driven by reagent and software demand. Management raised full-year guidance to 5% growth, citing AI-related demand and operational efficiencies. The company expects sustainable margins and plans to divest its China immunodiagnostics business in 2027. Key growth areas include reagents and Signals software, with AI-native offerings launching in 2026.

finance.yahoo.com7 min
NOV 3
$RVTYHighAI 9/10

Revvity Shares Jump Nearly 6% as Q3 Earnings Beat Forecasts and 2026 Guidance Improves

Revvity (RVTY) shares rose 5.55% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.37 vs. $1.30 expected. Revenue grew 4% YoY to $729M, surpassing forecasts. Pro forma revenue, excluding China Immunodiagnostics, increased 7% to $710M. Life Sciences revenue grew 10.8% to $380M, while Diagnostics saw a 2% reported decline but 4% pro forma growth.

finance.yahoo.com5 min
NOV 3
$RVTYHighAI 8/10

Revvity Q3 2026 slides: strong growth, margin expansion lift outlook

Revvity reported Q3 2026 revenue of $710M, up 7% YoY, with adjusted operating margins expanding to 29.4%. EPS grew 21% to $1.37. The company raised full-year guidance, citing strong demand and operational improvements. Life Sciences and Diagnostics segments showed growth, with the Americas and Europe outperforming Asia-Pacific. Revvity's stock surged 8.85% premarket to $165.01.

investing.com2 min
NOV 3
$RVTYHighAI 8/10

Revvity Announces Financial Results for the Third Quarter of 2026

REVVITY, INC. (RVTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE November 3, 2026 Revvity Announces Financial Results for the Third Quarter of 2026 • Revenue of $729 million; pro forma revenue of $710 million; 7% pro forma revenue growth; 7% pro forma organic revenue growth • GAAP EPS from continuing operations of $0.56 ;

SEC EDGAR 8-K2 min
NOV 3
$RVTYHighAI 8/10

Why is Revvity stock surging today?

Revvity (RVTY) stock rose 8.8% in pre-market trading after its Q3 2026 earnings beat estimates, with adjusted EPS of $1.37 and revenue of $729M. The company raised its full-year guidance, citing strong segment growth and margin expansion. CEO Prahlad Singh highlighted broad-based growth. The move was driven by company-specific news, not broader market trends. TD Cowen had previously raised its price target to $175.

investing.com2 min